top of page

Discovery of a novel anti-metastatic BCL3 inhibitor

Luke Piggott

1 Nov 2021

Publication describing the identification and development of TNAT-101 parent compound

TNA_LOGO-01.png

SCIENCE

ABOUT

LEADERSHIP

NEWS
CONTACT

EMAIL
Information@tnatherapeutics.com

OFFICES

TNA Therapeutics Inc, New York

TNA Therapeutics Ltd, London

TNA Therapeutics Sarl, Lausanne

SUBSCRIBE

To receive the latest TNA non-confidential deck and get the latest updates from TNA Therapeutics on new research, news and upcoming events, leave your email below!

Thanks for submitting!

Targeting Cancer At The Root

Copyright © 2022-2023 TNA Therapeutics 

  • LinkedIn
bottom of page